Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
NCT00590824
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
23
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
hu14.18-IL2
DRUG:
hu14.18-IL2
Sponsor
University of Wisconsin, Madison
Collaborators
[object Object]
[object Object]